Clinical Trials & Results
Search or filter the listing below to find a trial or results of a completed trial.
Showing 20 of 238 Results
All Results
No results found
Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.
Clear Filters
A Pharmacokinetic and Safety study comparing Fluticasone Propionate and Albuterol Sulfate to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
- Condition(s):
- Respiratory
- Status:
- Recruiting
- Requirements:
- 4 Years to 11 Years
- Interventions:
- Drug: TEV-56248
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
- Condition(s):
- Relapsing Remitting Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 50 Years
- Interventions:
- Drug: laquinimod 0.3 | Drug: laquinimod 0.6 | Other: Placebo
A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy Safety and Efficacy Study (TOPAS-MSA)
- Condition(s):
- Multiple System Atrophy
- Status:
- Recruiting
- Requirements:
- 30 Years and older
- Interventions:
- Drug: TEV-56286 (emrusolmin, anle138b)
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
- Condition(s):
- Vitiligo
- Status:
- Recruiting
- Requirements:
- 18 Years to 75 Years
- Interventions:
- Drug: TEV-53408
Absolute Bioavailability of Reslizumab in Healthy Subjects
- Condition(s):
- Absolute Bioavailability
- Status:
- Completed
- Requirements:
- 18 Years to 45 Years
- Interventions:
- Drug: Reslizumab IV | Drug: Reslizumab SC
Adenovirus Vaccine Pregnancy Registry
- Condition(s):
- Adenovirus
- Status:
- Withdrawn
- Requirements:
- 17 Years to 50 Years
Albuterol HFA MDI in Pediatric Participants With Asthma
- Condition(s):
- Asthma
- Status:
- Completed
- Requirements:
- 4 Years to 11 Years
- Interventions:
- Drug: Albuterol | Drug: Placebo | Drug: Proventilֲ® HFA
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
- Condition(s):
- Chronic Obstructive Pulmonary Disease
- Status:
- Terminated
- Requirements:
- 20 Years to 75 Years
- Interventions:
- Drug: TV48108 | Drug: Placebo
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
- Condition(s):
- Migraine Prophylaxis
- Status:
- Completed
- Requirements:
- 18 Years to 70 Years
- Interventions:
- Drug: Fremanezumab | Drug: Placebo
Assess Safety and PK of ADASUVE® in Children and Adolescents Using an Antipsychotic Medication
- Condition(s):
- BiPolar
- Status:
- Completed
- Requirements:
- 10 Years to 17 Years
- Interventions:
- Drug: ADASUVEֲ®
Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older
- Condition(s):
- Seasonal Female, Maleergic Rhinitis | Hayfever
- Status:
- Completed
- Requirements:
- 12 Years and older
- Interventions:
- Drug: Beclomethasone dipropionate HFA Nasal Aerosol | Drug: Placebo
Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo
- Condition(s):
- Relapsing Remitting Multiple Sclerosis
- Status:
- Completed
- Requirements:
- 18 Years to 55 Years
- Interventions:
- Drug: Glatiramer acetate (GA) | Drug: Placebo
Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
- Condition(s):
- Growth Hormone Deficiency
- Status:
- Completed
- Requirements:
- 20 Years to 60 Years
- Interventions:
- Drug: hGH-ViaDermג„¢ System (hGH or somatropin) | Device: hGH-ViaDermג„¢ System
Assessment of LBR-101 In Chronic Migraine
- Condition(s):
- Chronic Migraine
- Status:
- Completed
- Requirements:
- 18 Years to 65 Years
- Interventions:
- Biological: LBR-101 High Dose | Biological: LBR-101 Low Dose | Biological: Placebo
Azilect + Antidepressant Chart Review
- Condition(s):
- Serotonin Syndrome
- Status:
- Completed
- Requirements:
- Child, Adult, Older Adult
- Interventions:
- Drug: Group R+AD Rasagiline + Antidepressant | Drug: Group R Rasagiline | Drug: Group AD Anti-PD + Antidepressant
Azilect® In Wearing-Off
- Condition(s):
- Parkinson's Disease
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Drug: Azilectֲ®
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
- Condition(s):
- Chemotherapy-induced Neutropenia
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Biological: Neugranin | Drug: Pegfilgrastim | Drug: Chemotherapy
Beclomethasone Dipropionate in Participants At Least 12 Years Old With Persistent Asthma
- Condition(s):
- Asthma
- Status:
- Completed
- Requirements:
- 12 Years and older
- Interventions:
- Drug: Beclomethasone dipropionate | Drug: Placebo | Drug: Albuterol/salbutamol
Bendamustine Hydrochloride and Rituximab Compared With R-CVP or R-CHOP in Patients With Lymphoma
- Condition(s):
- Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma
- Status:
- Completed
- Requirements:
- 18 Years and older
- Interventions:
- Drug: bendamustine | Drug: rituximab | Drug: vincristine | Drug: prednisone | Drug: cyclophosphamide | Drug: doxorubicin
Bendamustine Hydrochloride for the Treatment of Relapsed or Refractory Acute Leukemia
- Condition(s):
- Leukemia
- Status:
- Completed
- Requirements:
- 1 Year to 20 Years
- Interventions:
- Drug: Bendamustine
